Gordan Srkalović

9.8k total citations · 1 hit paper
91 papers, 3.6k citations indexed

About

Gordan Srkalović is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Gordan Srkalović has authored 91 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 28 papers in Molecular Biology and 16 papers in Hematology. Recurrent topics in Gordan Srkalović's work include Multiple Myeloma Research and Treatments (16 papers), Viral-associated cancers and disorders (12 papers) and Cancer Treatment and Pharmacology (12 papers). Gordan Srkalović is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Viral-associated cancers and disorders (12 papers) and Cancer Treatment and Pharmacology (12 papers). Gordan Srkalović collaborates with scholars based in United States, Hungary and Canada. Gordan Srkalović's co-authors include Andrew V. Schally, Mohamad A. Hussein, Bart Barlogie, James R. Berenson, Seema Singhal, Kenneth C. Anderson, Sundar Jagannath, Paul G. Richardson, Tommie W. Redding and Dixie Esseltine and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gordan Srkalović

82 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

2014 482 citations William E. Barlow, Gabriel N. Hortobágyi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gordan Srkalović United States	31	1.8k	1.6k	1.3k	556	389	91	3.6k
Sun‐Young Kong South Korea	32	1.3k 0.8×	1.4k 0.9×	425 0.3×	683 1.2×	498 1.3×	204	3.7k
Trivadi S. Ganesan India	32	1.2k 0.7×	1.7k 1.1×	484 0.4×	590 1.1×	365 0.9×	166	3.8k
Kazuhiko Ino Japan	39	2.1k 1.2×	1.7k 1.1×	287 0.2×	751 1.4×	551 1.4×	192	5.5k
Anneke Geurts‐Moespot Netherlands	30	524 0.3×	804 0.5×	822 0.6×	531 1.0×	233 0.6×	75	2.9k
Catherine Lofton–Day United States	20	1.3k 0.7×	1.5k 1.0×	262 0.2×	1.1k 2.0×	572 1.5×	32	3.6k
Catherine Wheeler United States	30	1.7k 1.0×	1.1k 0.7×	1.1k 0.8×	473 0.9×	520 1.3×	73	3.6k
Barbara Schmalfeldt Germany	33	1.5k 0.8×	1.2k 0.8×	327 0.2×	855 1.5×	386 1.0×	130	4.2k
Andrzej Jakubowiak United States	43	3.1k 1.7×	4.2k 2.7×	4.1k 3.1×	201 0.4×	91 0.2×	262	6.3k
Daniel J. Lindner United States	41	1.5k 0.8×	3.2k 2.0×	211 0.2×	1.1k 2.0×	430 1.1×	133	5.4k
Cornelius F. Waller Germany	31	1.0k 0.6×	867 0.6×	623 0.5×	171 0.3×	419 1.1×	158	3.2k

Countries citing papers authored by Gordan Srkalović

Since Specialization

Citations

This map shows the geographic impact of Gordan Srkalović's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordan Srkalović with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordan Srkalović more than expected).

Fields of papers citing papers by Gordan Srkalović

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordan Srkalović. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordan Srkalović. The network helps show where Gordan Srkalović may publish in the future.

Co-authorship network of co-authors of Gordan Srkalović

This figure shows the co-authorship network connecting the top 25 collaborators of Gordan Srkalović. A scholar is included among the top collaborators of Gordan Srkalović based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordan Srkalović. Gordan Srkalović is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pierson, Sheila K., Adam Bagg, Mary Jo Lechowicz, et al.. (2025). Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease.. Journal of Clinical Oncology. 43(16_suppl). 7082–7082.

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2024). Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400026–e2400026. 1 indexed citations

Riess, Jonathan W., Jieling Miao, Paul Wheatley‐Price, et al.. (2024). 1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A. Annals of Oncology. 35. S832–S833. 1 indexed citations

Bagg, Adam, Mary Jo Lechowicz, Daisy Alapat, et al.. (2024). The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease. Blood. 144(Supplement 1). 1156–1156. 1 indexed citations

Pierson, Sheila K., Megan S. Lim, Gordan Srkalović, et al.. (2023). Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Advances. 7(21). 6652–6664. 16 indexed citations

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2023). Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3115–3115.

Fajgenbaum, David C., Sheila K. Pierson, Karan Kanhai, et al.. (2022). The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British Journal of Haematology. 198(2). 307–316. 4 indexed citations

Pierson, Sheila K., Yue Ren, Adam Bagg, et al.. (2022). Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease. Blood. 140(Supplement 1). 6520–6521. 2 indexed citations

Pierson, Sheila K., Adam Bagg, Daisy Alapat, et al.. (2021). Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. Blood. 138(Supplement 1). 1622–1622. 2 indexed citations

10.

Budd, G. Thomas, William E. Barlow, Halle C. F. Moore, et al.. (2013). S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.. Journal of Clinical Oncology. 31(15_suppl). CRA1008–CRA1008. 8 indexed citations

11.

Srkalović, Gordan, et al.. (2010). Relative dose intensity of systemic chemotherapy in an outpatient cancer center. SHILAP Revista de lepidopterología. 2 indexed citations

12.

Lazaryan, Aleksandr, Rachid Baz, Mohamad A. Hussein, et al.. (2010). Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma. Blood. 116(21). 1967–1967. 1 indexed citations

13.

Olsen, Brian, Gordan Srkalović, Marcia Hall, & Ellen D. McPhail. (2009). Cyclin D1 positive follicular lymphoma. Journal of Clinical Pathology. 62(9). 855–857. 4 indexed citations

14.

Baz, Rachid, Esteban Walker, Mohamed A. Karam, et al.. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 17(12). 1766–1771. 116 indexed citations

15.

Richardson, Paul G., Hannah Briemberg, Sundar Jagannath, et al.. (2006). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology. 24(19). 3113–3120. 480 indexed citations

16.

Richardson, Paul G., Bart Barlogie, James R. Berenson, et al.. (2006). Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:. Cancer. 106(6). 1316–1319. 115 indexed citations

17.

Hussein, Mohamad A., Mary Ann Karam, C. Brand, et al.. (2004). Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.. Blood. 104(11). 208–208. 8 indexed citations

18.

Srkalović, Gordan, et al.. (2002). Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma. Medical Oncology. 19(4). 219–226. 38 indexed citations

19.

Pinski, J., Andrew V. Schally, T. Yano, et al.. (1995). Evaluation of the in vitro and in vivo activity of the l‐, d,l‐ and d‐Cit⁶ forms of the LH‐RH antagonist Cetrorelix (SB‐75). International journal of peptide & protein research. 45(5). 410–417. 9 indexed citations

20.

Srkalović, Gordan, James L. Wittliff, & Andrew V. Schally. (1990). Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.. PubMed. 50(6). 1841–6. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact